APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hormone Refractory Prostate Cancer (HRPCA)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hormone Refractory Prostate Cancer (HRPCA) Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchHormone Refractory Prostate Cancer (HRPCA) Industry Research Report 2026104 pages · $2,950 USDIndustry Growth & TrendsGlobal Hormone Refractory Prostate Cancer (HRPCA) Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Hormone Refractory Prostate Cancer (HRPCA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hormone Refractory Prostate Cancer (HRPCA) Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Hormone Refractory Prostate Cancer (HRPCA) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hormone Refractory Prostate Cancer (HRPCA) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hormone Refractory Prostate Cancer (HRPCA) market include Sanofi S.A, Johnson & Johnson, Astellas Inc and Dendreon Corporation, Bayer AG, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hormone Refractory Prostate Cancer (HRPCA) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hormone Refractory Prostate Cancer (HRPCA) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hormone Refractory Prostate Cancer (HRPCA) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hormone Refractory Prostate Cancer (HRPCA) market.

Hormone Refractory Prostate Cancer (HRPCA) Segment by Company

Sanofi S.A

Johnson & Johnson

Astellas Inc

Dendreon Corporation, Bayer AG

Hormone Refractory Prostate Cancer (HRPCA) Segment by Type

Vaccines

Cytotoxic Agents

Anti-Androgens

Radio-Pharmaceuticals

Hormone Refractory Prostate Cancer (HRPCA) Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Others

Hormone Refractory Prostate Cancer (HRPCA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hormone Refractory Prostate Cancer (HRPCA) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hormone Refractory Prostate Cancer (HRPCA) key companies, revenue, market share, and recent developments.

3. To split the Hormone Refractory Prostate Cancer (HRPCA) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hormone Refractory Prostate Cancer (HRPCA) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hormone Refractory Prostate Cancer (HRPCA) significant trends, drivers, influence factors in global and regions.

6. To analyze Hormone Refractory Prostate Cancer (HRPCA) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Refractory Prostate Cancer (HRPCA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hormone Refractory Prostate Cancer (HRPCA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Refractory Prostate Cancer (HRPCA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hormone Refractory Prostate Cancer (HRPCA) industry.

Chapter 3: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hormone Refractory Prostate Cancer (HRPCA) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hormone Refractory Prostate Cancer (HRPCA) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hormone Refractory Prostate Cancer (HRPCA) Industry Trends Table 2. Hormone Refractory Prostate Cancer (HRPCA) Industry Drivers Table 3. Hormone Refractory Prostate Cancer (HRPCA) Industry Opportunities and Challenges Table 4. Hormone Refractory Prostate Cancer (HRPCA) Industry Restraints Table 5. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Company (2021-2026) Table 7. Global Hormone Refractory Prostate Cancer (HRPCA) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hormone Refractory Prostate Cancer (HRPCA) Key Company Manufacturing Base & Headquarters Table 9. Global Hormone Refractory Prostate Cancer (HRPCA) Company, Product Type & Application Table 10. Global Hormone Refractory Prostate Cancer (HRPCA) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hormone Refractory Prostate Cancer (HRPCA) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vaccines Table 15. Significant Companies of Cytotoxic Agents Table 16. Significant Companies of Anti-Androgens Table 17. Significant Companies of Radio-Pharmaceuticals Table 18. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type (2021-2026) Table 22. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Specialty Clinics Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Ambulatory Surgical Centers Table 26. Significant Companies of Others Table 27. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application (2021-2026) Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application (2027-2032) Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Region (2021-2026) Table 35. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Region (2027-2032) Table 37. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Market Share by Country (2021-2026) Table 40. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Market Share by Country (2027-2032) Table 42. Sanofi S.A Company Information Table 43. Sanofi S.A Business Overview Table 44. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 46. Sanofi S.A Recent Development Table 47. Johnson & Johnson Company Information Table 48. Johnson & Johnson Business Overview Table 49. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 51. Johnson & Johnson Recent Development Table 52. Astellas Inc Company Information Table 53. Astellas Inc Business Overview Table 54. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 56. Astellas Inc Recent Development Table 57. Dendreon Corporation, Bayer AG Company Information Table 58. Dendreon Corporation, Bayer AG Business Overview Table 59. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 61. Dendreon Corporation, Bayer AG Recent Development Table 62. Research Programs/Design for This Report Table 63. Authors List of This Report Table 64. Secondary Sources Table 65. Primary Sources List of Figures Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Product Image Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 4. Global Hormone Refractory Prostate Cancer (HRPCA) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vaccines Image Figure 8. Cytotoxic Agents Image Figure 9. Anti-Androgens Image Figure 10. Radio-Pharmaceuticals Image Figure 11. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type (2021-2032) Figure 14. Specialty Clinics Image Figure 15. Hospitals Image Figure 16. Ambulatory Surgical Centers Image Figure 17. Others Image Figure 18. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application (2021-2032) Figure 21. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032) & (US$ Million) Figure 24. North America Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032) & (US$ Million) Figure 30. South America Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Cytotoxic Agents
  • Anti-Androgens
  • Radio-Pharmaceuticals
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Sanofi S.A
  • Johnson & Johnson
  • Astellas Inc
  • Dendreon Corporation, Bayer AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
  1. 2.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
  2. 2.2 Hormone Refractory Prostate Cancer (HRPCA) Industry Drivers
  3. 2.3 Hormone Refractory Prostate Cancer (HRPCA) Industry Opportunities and Challenges
  4. 2.4 Hormone Refractory Prostate Cancer (HRPCA) Industry Restraints
3 Hormone Refractory Prostate Cancer (HRPCA) Market by Company
  1. 3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Company Revenue Ranking in 2025
  2. 3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Company (2021-2026)
  3. 3.3 Global Hormone Refractory Prostate Cancer (HRPCA) Company Ranking (2024-2026)
  4. 3.4 Global Hormone Refractory Prostate Cancer (HRPCA) Company Manufacturing Base and Headquarters
  5. 3.5 Global Hormone Refractory Prostate Cancer (HRPCA) Company Product Type and Application
  6. 3.6 Global Hormone Refractory Prostate Cancer (HRPCA) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hormone Refractory Prostate Cancer (HRPCA) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hormone Refractory Prostate Cancer (HRPCA) Market by Type
  1. 4.1 Hormone Refractory Prostate Cancer (HRPCA) Type Introduction
  2. 4.1.1 Vaccines
  3. 4.1.2 Cytotoxic Agents
  4. 4.1.3 Anti-Androgens
  5. 4.1.4 Radio-Pharmaceuticals
  6. 4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Type
  7. 4.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Type (2021-2032)
  9. 4.2.3 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type (2021-2032)
5 Hormone Refractory Prostate Cancer (HRPCA) Market by Application
  1. 5.1 Hormone Refractory Prostate Cancer (HRPCA) Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Ambulatory Surgical Centers
  5. 5.1.4 Others
  6. 5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Application
  7. 5.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Application (2021-2032)
  9. 5.2.3 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application (2021-2032)
6 Hormone Refractory Prostate Cancer (HRPCA) Regional Value Analysis
  1. 6.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032)
  7. 6.3.2 North America Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032)
  10. 6.4.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032)
  16. 6.6.2 South America Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Country, 2025 VS 2032
7 Hormone Refractory Prostate Cancer (HRPCA) Country-level Value Analysis
  1. 7.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi S.A
  2. 8.1.1 Sanofi S.A Company Information
  3. 8.1.2 Sanofi S.A Business Overview
  4. 8.1.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  6. 8.1.5 Sanofi S.A Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Astellas Inc
  14. 8.3.1 Astellas Inc Company Information
  15. 8.3.2 Astellas Inc Business Overview
  16. 8.3.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  18. 8.3.5 Astellas Inc Recent Developments
  19. 8.4 Dendreon Corporation, Bayer AG
  20. 8.4.1 Dendreon Corporation, Bayer AG Company Information
  21. 8.4.2 Dendreon Corporation, Bayer AG Business Overview
  22. 8.4.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  24. 8.4.5 Dendreon Corporation, Bayer AG Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst